PHP
KPTI icon

Parkman Healthcare Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Parkman Healthcare Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,053
Closed -$2.29M – 90
2020
Q2 		$2.29M Sell
8,053
-6,334
-44% -$1.87M 0.64% 52
2020
Q1 		$4.15M Sell
14,387
-18,946
-57% -$5.23M 1.92% 18
2019
Q4 		$9.59M Buy
+33,333
New +$7.23M 2.77% 11

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Parkman Healthcare Partners's KPTI Position: Q3 2020 in Review

Parkman Healthcare Partners sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 8,053 shares — an estimated $2.29M sold.

Parkman Healthcare Partners first reported a position in KPTI in Q4 2019 and held it in 3 quarters. The position peaked at $9.59M in Q4 2019. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

  • Parkman Healthcare Partners reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 8,053 Karyopharm Therapeutics shares in Q3 2020, an estimated $2.29M.
  • Parkman Healthcare Partners first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's Karyopharm Therapeutics position peaked at $9.59M in Q4 2019.
  • 157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.